Ionis Pharmaceuticals, Inc.
LSE: 0JDI.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Brett Monia
- Employees
- 1,069
- Headquarters
- Carlsbad, United States
- IPO year
- 2018
- Market cap
- $12.3B
- Website
- https://www.ionispharma.com
Loading 0JDI…
Loading profile data…Frequently asked questions about 0JDI
What does Ionis Pharmaceuticals, Inc. (0JDI.L) do?
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
Where does 0JDI.L trade?
Ionis Pharmaceuticals, Inc. (0JDI.L) trades on the London Stock Exchange.
What sector is 0JDI.L in?
Ionis Pharmaceuticals, Inc. (0JDI.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Ionis Pharmaceuticals, Inc.?
Brett Monia is the chief executive officer of Ionis Pharmaceuticals, Inc. (0JDI.L).
Where is Ionis Pharmaceuticals, Inc. headquartered?
Ionis Pharmaceuticals, Inc. is headquartered in United States.
Does 0JDI.L pay a dividend?
Ionis Pharmaceuticals, Inc. (0JDI.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0JDI.L go public?
Ionis Pharmaceuticals, Inc. (0JDI.L) completed its initial public offering in 2018.